Results 31 to 40 of about 223,608 (200)
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition [PDF]
Overcoming de novo and acquired resistance to anticancer drugs that target signaling networks is a formidable challenge for drug design and effective cancer therapy.
Bown, James L. +5 more
core +4 more sources
Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation [PDF]
A tumor suppressor gene at 10q 23.3, designated PTEN, encoding a dual specificity phosphatase with lipid and protein phosphatase activity, has been shown to play an important role in the pathogenesis of a variety of human cancers. Germline mutations in PTEN cause Cowden syndrome (CS), which is characterized by multiple hamartomas and a high risk of ...
X P, Zhou +5 more
openaire +2 more sources
Folate-targeted PTEN/AKT/P53 signaling pathway promotes apoptosis in breast cancer cells
Objective Folate deficiency is closely related to the occurrence of human tumors and plays an important role in cell growth, differentiation, repair, and host defense.
Wang Hexian +6 more
doaj +1 more source
Background: To investigate the effect and potential molecular mechanisms of Dipsacoside B (DB), an herb monomer extracted from Dipsacusasper or Lonicera macranthoides, on the migration and proliferation of vascular smooth muscle cells (VSMCs) and balloon-
Wenjuan Quan +7 more
doaj +1 more source
Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L. +4 more
core +5 more sources
A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT [PDF]
Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway ...
Boiko, Andrei +6 more
core +3 more sources
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer [PDF]
Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to advanced prostate cancer progression and poor clinical outcome. Accordingly, several therapeutic approaches are currently being explored to combat PTEN-deficient tumors. These include
Daniel J. Turnham +4 more
openaire +3 more sources
Fei Wu,1– 3,* Jie Chen,4,* Kang Yao,1 Daming Fan,5 Minglei Wang,2 Yongjun Liu,1 Shouhu Xin,1 Zeqiang Sun,1 Shun Li,1 Yang Sun,6 Qingyong Liu1 1Department of Urology, the First Affiliated Hospital of Shandong First Medical University, Shandong ...
Wu F +10 more
doaj
Background Nephrotoxicity, especially acute kidney injury (AKI), is the main dose-limiting toxicity of cisplatin. Although recent studies showed that curcumin prevented cisplatin-induced AKI effectively, further studies to understand the mechanism are ...
Si-Jia Huang +12 more
doaj +1 more source
Upregulated wnt-11 and mir-21 expression trigger epithelial mesenchymal transition in aggressive prostate cancer cells [PDF]
Prostate cancer (PCa) is the second-leading cause of cancer-related death among men. microRNAs have been identified as having potential roles in tumorigenesis.
Arisan, E.D. +15 more
core +1 more source

